Vamil Divan

Stock Analyst at Guggenheim

(2.61)
# 589
Out of 5,332 analysts
278
Total ratings
54.46%
Success rate
30.60%
Average return
45 Stocks
Name Action PT Current % Upside Ratings Updated
ABBV AbbVie
Maintains: Strong Buy
214 216
195.88 10.27% 22 Apr 29, 2025
UNCY Unicycive Therapeuti...
Initiates Coverage On: Buy
6
0.65 823.08% 1 Apr 21, 2025
MRK Merck & Co
Reiterates: Buy
115 115
82.86 38.79% 9 Apr 17, 2025
TVTX Travere Therapeutics
Reiterates: Buy
47 47
21.41 119.52% 8 Apr 14, 2025
ANIP ANI Pharmaceuticals
Reiterates: Buy
86 86
72.68 18.33% 10 Apr 11, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Neutral
n/a
n/a n/a 15 Apr 2, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
31
14.19 118.46% 1 Mar 25, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
10 10
2.87 248.43% 3 Mar 20, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
n/a
n/a n/a 17 Mar 18, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
59 61
25.39 140.25% 5 Feb 27, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
101 101
72.61 39.1% 6 Feb 25, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Neutral
n/a
n/a n/a 5 Jan 17, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
7 4
n/a n/a 6 Dec 10, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
6
0.77 679.22% 1 Sep 10, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 2 Jun 18, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
55
n/a n/a 1 Apr 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
245 330
n/a n/a 7 Jan 26, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
19 20
7.17 178.94% 9 Sep 7, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
21 18
n/a n/a 2 Aug 18, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Buy
26
0.39 6566.67% 2 Jun 15, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
35 40
n/a n/a 3 Jun 12, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
8 9
0.96 837.5% 2 Apr 3, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Neutral
n/a
n/a n/a 1 Mar 1, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
13 2
n/a n/a 5 Nov 15, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
27 19
15.17 25.25% 7 Aug 10, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
95 98
109.7 -10.67% 8 Aug 8, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
36 34
31.4 8.28% 7 Jul 28, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
20 10
1.28 681.25% 3 May 25, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
51 49
116.5 -57.94% 3 May 3, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
315 356
823.24 -56.76% 15 May 2, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
8 6
4.64 29.31% 1 Mar 16, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
144 154
22.55 582.93% 9 Mar 3, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Buy
15
11.97 25.31% 5 May 6, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
n/a
n/a n/a 6 Dec 13, 2019
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
7 4
n/a n/a 6 Nov 8, 2019
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Neutral
11 19
n/a n/a 8 Sep 17, 2019
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Assumes: Neutral
35
n/a n/a 13 Aug 5, 2019
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Assumes: Neutral
n/a
n/a n/a 13 Jul 10, 2019
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Assumes: Outperform
36 30
n/a n/a 4 May 21, 2019
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
161 155
n/a n/a 10 Mar 7, 2019
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Assumes: Outperform
15
3.56 321.35% 4 Aug 15, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
58 61
49.95 22.12% 5 Jul 27, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
103
1.05 9709.52% 3 Jan 17, 2018
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
45 55
n/a n/a 1 Sep 19, 2017
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Outperform
66 120
n/a n/a 4 Dec 20, 2016